Exhibit 99.1

 

 

Report of Voting Results

Aptose Biosciences Inc.

 

In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual and special meeting of shareholders of Aptose Biosciences Inc. (the “Corporation”) held on June 6, 2017 in Toronto, Ontario.

 

1. By a resolution passed by a majority of the votes cast by a show of hands, each of the following directors were elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed:

 

Nominee   Votes For   % Votes For   Votes Withheld   % Votes
                Withheld
Dr. Denis Burger   4,942,137   94.88   266,640   5.12
Dr. Erich Platzer   4,942,126   94.88   266,651   5.12
Dr. William G. Rice   4,939,458   94.83   269,319   5.17
Dr. Bradley Thompson   4,931,745   94.68   277,032   5.32
Dr. Mark D. Vincent   4,943,710   94.91   265,067   5.09
Warren Whitehead   4,944,586   94.93   264,191   5.07

 

2. By a resolution passed by a majority of the votes cast by a show of hands (of which approximately 99.57% of the votes represented by proxy voted in favour and approximately 0.43% of the votes represented by proxy withheld from voting), KPMG LLP was re-appointed as auditor of the Corporation to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration.

 

 

In total, approximately 26.17% of the issued and outstanding shares were represented in person or by proxy at the meeting.

 

Yours very truly,

 

/s/ Gregory Chow

 

Gregory Chow

Senior Vice President and Chief Financial Officer